Dr. Ariel Ann Nelson, MD

Dr. Nelson practices at Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health.

Dr. Nelson's NPI, 1083956148, was assigned on March 26, 2013. Dr. Nelson graduated from State University of New York at Buffalo School of Medicine in 2013. Dr. Nelson holds Wisconsin license 63243.

Dr. Nelson's primary practice is Froedtert Hospital, at 9200 W Wisconsin Ave, Milwaukee, WI 53226 in Milwaukee County. The practice phone is (414) 805-3000.

Dr. Nelson's primary practice is Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health. Dr. Nelson is also affiliated with SSM Health St. Mary's Hospital - Madison. The medical group on file is Froedtert & the Medical College of Wisconsin Community Physicians. Dmand AI also links Dr. Nelson to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nelson practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nelson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nelson is licensed in Wisconsin.

CMS data shows 458 Medicare services from Dr. Nelson across 6 procedure codes in 2024, for 126 Medicare patients. Medicare paid $23,780 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 126 Medicare patients who saw Dr. Nelson in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have cancer, and 73% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nelson's median patient age at 70, with 15% women.

In 2024, Dr. Nelson wrote 528 Medicare Part D claims for 101 patients. 76% of them were for generic drugs. CMS names the drug for 402 of them, across 13 drugs with 11 or more claims each, at $1,020,362 in total drug cost. In 2023, CMS named 506 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Nelson for performance year 2024, reported as part of a group. Dr. Nelson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nelson as offering telehealth.

Dmand AI links 18 papers to Dr. Nelson, published from 2016 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Immune Checkpoint Inhibitors, Carcinoma, Transitional Cell and Urinary Bladder Neoplasms. Dr. Nelson has published most often in Clin Genitourin Cancer. Dr. Nelson's most frequent co-authors are Christopher J. Hoimes, DO, Petros Grivas, MD and Ali Raza Khaki, MD.

Dmand AI links Dr. Nelson to 1 clinical trial. Conditions studied include Anus Neoplasms and Anus Diseases.

CMS Open Payments shows 43 general payments to Dr. Nelson from 19 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 48% of the total. Merck Sharp & Dohme Corporation paid the most, $2,328.

Dr. Nelson graduated from State University of New York at Buffalo School of Medicine in 2013.